0.71 USD
▼-0.04-4.96%
盘后 0.73 +2.63%
2026-11-20
市值
$44.12M
市盈率
—
EPS
-1.55
股息率
—
52 周区间
0.62 – 5.50
成交量
1.44M
Beta
1.35
目标价
9.50
52W 低 0.6252W 高 5.50
价格走势
公司简介
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an...